Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16993001 | 0.86 | EPHX1 (0.50) | GPR119EPHX1HPGDALDH1A1RECQL | |
| SCHEMBL13086399 | 0.82 | GPR119 (0.54) | GPR119HPGD | |
| SCHEMBL5195241 | 0.81 | EPHX1 (0.48) | GPR119EPHX1HPGDALDH1A1RECQL | |
| SCHEMBL18429019 | 0.81 | GPR119 (0.47) | GPR119EPHX1HPGDRECQL | |
| SCHEMBL18429026 | 0.80 | GPR119 (0.51) | GPR119EPHX1HPGDRECQL | |
| SCHEMBL4644042 | 0.80 | EPHX1 (0.52) | GPR119EPHX1HPGDALDH1A1RECQL | |
| SCHEMBL18429061 | 0.79 | GPR119 (0.49) | GPR119EPHX1HPGDRECQL | |
| SCHEMBL7580625 | 0.78 | LIMK2 (0.48) | GPR119EPHX1HPGDALDH1A1RECQL | |
| SCHEMBL17271531 | 0.78 | RECQL (0.45) | GPR119EPHX1HPGDALDH1A1RECQL | |
| SCHEMBL18494970 | 0.78 | GPR119 (0.43) | GPR119EPHX1HPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822262-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| CN-107949558-B | Muscarinic agonists | 赫普泰雅治疗有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-11091456-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| US-11091456-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| EP-3822262-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2021-05-19 | — | — | EP | disclosed |
| EP-3822262-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2021-05-19 | — | — | EP | disclosed |
| EP-3331869-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| EP-3331869-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-20190270718-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-20190270718-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-20180022726-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022726-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022726-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9758506-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9758506-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9758506-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170037025-A1 | Muscarinic Agonists | NXERA PHARMA UK LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| WO-2017021730-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| US-20170037025-A1 | Muscarinic Agonists | NXERA PHARMA UK LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| US-20170037025-A1 | Muscarinic Agonists | NXERA PHARMA UK LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091456-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | GPR119 90/4885EPHX1 849/4885HPGD 2878/4885 |
| US-20180022726-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | GPR119 90/4885EPHX1 849/4885HPGD 2878/4885 |
| US-20190270718-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | GPR119 90/4885EPHX1 849/4885HPGD 2878/4885 |
| US-20170037025-A1 | Muscarinic Agonists | CHRM1, CHRM2, CHRM3 | GPR119 90/4885EPHX1 849/4885HPGD 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.